Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Savara Inc (SVRA)

Savara Inc (SVRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,767
  • Shares Outstanding, K 114,043
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,010 K
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.36
Trade SVRA with:

Options Overview Details

View History
  • Implied Volatility 99.33% ( -4.77%)
  • Historical Volatility 52.17%
  • IV Percentile 10%
  • IV Rank 5.78%
  • IV High 1,093.49% on 11/08/21
  • IV Low 38.29% on 06/17/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,698
  • Open Int (30-Day) 2,659

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.07
  • Prior Year -0.07
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +14.07%
on 09/27/22
1.5800 -2.53%
on 10/03/22
+0.0900 (+6.21%)
since 09/02/22
3-Month
1.3500 +14.07%
on 09/27/22
1.9100 -19.37%
on 07/11/22
unch (unch)
since 07/01/22
52-Week
1.0200 +50.98%
on 03/14/22
1.9100 -19.37%
on 07/11/22
+0.2000 (+14.93%)
since 10/01/21

Most Recent Stories

More News
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

SVRA : 1.5400 (-0.65%)
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6...

SVRA : 1.5400 (-0.65%)
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright...

SVRA : 1.5400 (-0.65%)
Savara Announces Resignation of Chief Medical Officer

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical...

SVRA : 1.5400 (-0.65%)
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA)...

SVRA : 1.5400 (-0.65%)
Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2022 and provided a business...

SVRA : 1.5400 (-0.65%)
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International...

SVRA : 1.5400 (-0.65%)
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks

Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.

LGL : 11.90 (+5.12%)
HHS : 11.13 (-0.18%)
SVRA : 1.5400 (-0.65%)
3 Top Breakout Stocks to Add to Your Portfolio Now

Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.

LGL : 11.90 (+5.12%)
HHS : 11.13 (-0.18%)
SVRA : 1.5400 (-0.65%)
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.

ASRT : 2.31 (+1.76%)
SVRA : 1.5400 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 1.6467
2nd Resistance Point 1.6133
1st Resistance Point 1.5767
Last Price 1.5400
1st Support Level 1.5067
2nd Support Level 1.4733
3rd Support Level 1.4367

See More

52-Week High 1.9100
Fibonacci 61.8% 1.5700
Last Price 1.5400
Fibonacci 50% 1.4650
Fibonacci 38.2% 1.3600
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar